Three more measles cases confirmed in county
The ACHD had been monitoring a household for more cases after confirming an eleventh measles case toward the end of last week.
Ashtabula County Health Commissioner Jay Becker said the eleventh case was an unvaccinated adult who traveled internationally.
The ADHD was monitoring people in the the eleventh case's household to determine whether others had the disease, Becker said.
'These suspect cases are now confirmed,' he said.
Becker said the three new cases were unvaccinated children.
The health department is monitoring another adult in the house to see if they develop symptoms, he said.
All five members of the household are isolating so they do not infect anyone else.
Becker said the ACHD is not aware of any other suspect cases in the county at this time.
No school districts are being affected by the measles outbreak.
The health department will update its numbers with any new cases if it gets them, Becker said.
The ACHD and the Ohio Department of Health confirmed the first case of the year in the state March 20, and later announced an outbreak for the country after confirming nine more cases March 25.
The original ten cases have completed their isolation period and are no longer infectious, Becker said.
The four newer cases are not connected to the previous ten, Becker said.
'We know how to stop this,' he said. 'It's getting a vaccine.'
Becker said all 14 cases in the county this year were in unvaccinated individuals.
'That should really be the story here,' he said.
The best way to fight measles is to get the MMR vaccine, Becker said.
'With something as serious as this, the vaccine is the best and only defense,' he said.
Becker encouraged people who are not sure of their vaccination status to get vaccinated, he said.
'I don't know how to stress this enough,' he said.
The ACHD offers walk-in vaccine clinics 9 a.m.-3:30 p.m. Monday, Tuesday and Friday at its office, at 12 West Jefferson St. in Jefferson.
Alongside the in-office clinics, the health department has a regular set of community neighborhood mobile clinics scheduled.
People can go to the ACHD's website, ashtabulacountyhealth.com, to see a list of clinics.
The department also schedules clinics for the Amish community.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
a day ago
- Time Business News
Benefits of Working Out on Adderall
Adderall is a prescription stimulant commonly used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by enhancing the levels of dopamine and norepinephrine in the brain, improving focus, alertness, and energy levels. While its primary purpose is medical, many people who take Adderall notice an impact on their physical activity, particularly when it comes to exercising. Combining Adderall with Working Out on Adderall can lead to unique benefits, though it should always be done carefully and under medical supervision. Understanding how Adderall influences exercise performance and fitness goals can help individuals make the most of their routines while staying safe. Several factors can influence why a treatment may not deliver the expected results. Lifestyle habits such as poor sleep, high stress, or an imbalanced diet can interfere with focus and energy levels. In some cases, the body may develop tolerance, making the prescription less effective over time. Additionally, incorrect dosage or interactions with other medications can also play a role. For some individuals, underlying health conditions may complicate response to treatment. These are among the common reasons for Adderall not working as expected, highlighting the importance of regular follow-ups with a healthcare professional for proper adjustments. One of the most noticeable benefits of working out on Adderall is the surge of energy it provides. Since Adderall stimulates the central nervous system, it can help combat fatigue and make physical activity feel less exhausting. For individuals who often struggle with motivation or low energy, Adderall can provide the boost needed to get started with a workout and maintain intensity throughout the session. This increased stamina can translate into longer exercise sessions, higher calorie burn, and improved endurance over time. People who run, cycle, or engage in other forms of cardio may find it easier to sustain their pace and push past their usual limits when on Adderall. Adderall's ability to sharpen focus extends beyond academics and work tasks—it can also enhance concentration during workouts. For individuals who struggle with staying present while exercising, this improved mental clarity can be highly beneficial. Instead of becoming distracted, people may find it easier to focus on their form, breathing, and technique. Whether lifting weights or performing yoga, maintaining proper focus can lead to safer and more effective workouts. By eliminating mental distractions, Adderall users may experience a more mindful connection to their physical activity, which can contribute to long-term progress and consistency. Staying motivated is one of the biggest challenges in maintaining a consistent fitness routine. Adderall can play a role in boosting motivation by increasing dopamine levels, which influence feelings of reward and pleasure. This means individuals may not only feel more driven to work out but also experience a greater sense of satisfaction afterward. When combined with the natural endorphins released during exercise, this can create a strong positive reinforcement loop. Over time, this can help individuals stick to their workout programs, establish healthy habits, and view exercise as a rewarding part of their daily lives. For those engaged in strength training, Adderall can provide advantages by improving both physical energy and mental concentration. Having the ability to focus intensely on lifting form and pushing through challenging sets can contribute to better performance and strength gains. Since Adderall reduces feelings of fatigue, it may also help individuals handle higher training volumes or complete more repetitions with good technique. While it does not build muscle directly, the enhanced intensity and focus during workouts can contribute to long-term improvements in strength and muscle development. Another potential benefit of working out on Adderall is its effect on weight management. Adderall is known to suppress appetite, which may make it easier for individuals to maintain a calorie deficit if they are aiming for weight loss. When combined with regular exercise, this can accelerate fat loss while preserving lean muscle mass. Additionally, the increased energy and stamina provided by Adderall can encourage more frequent and intense workouts, which further supports calorie burning and weight control. However, it is important for individuals to maintain proper nutrition, as reduced appetite can sometimes lead to insufficient food intake and nutrient deficiencies. Adderall's ability to heighten alertness can also improve the mind-body connection during workouts. This means individuals may become more aware of how their body feels while exercising, from muscle engagement to breathing patterns. Such awareness is particularly valuable for activities like yoga, pilates, or weightlifting, where precision and control play a key role in effectiveness. Developing a stronger mind-body connection can lead to better results, fewer injuries, and a more satisfying fitness experience overall. One of the indirect but valuable benefits of Adderall is its role in improving consistency. Many individuals who take Adderall for ADHD struggle with maintaining structured routines due to distraction, impulsivity, or lack of focus. By enhancing organization and motivation, Adderall can make it easier to stick to a workout schedule. Regular exercise consistency is one of the most important factors in achieving long-term fitness goals, whether they involve weight loss, muscle building, or improved cardiovascular health. Adderall may help bridge the gap between intention and action by keeping individuals on track with their commitments. While there are clear benefits of working out on Adderall, it is important to approach this combination responsibly. Adderall can increase heart rate and blood pressure, and intense physical activity can amplify these effects. Individuals should monitor how their body responds and consult their healthcare provider before combining Adderall with vigorous exercise. Staying hydrated, maintaining a balanced diet, and avoiding overexertion are essential for safety. Ultimately, the goal is to maximize the benefits of both Adderall and exercise without placing unnecessary strain on the body. Working out on Adderall can offer unique advantages such as improved energy, focus, motivation, and performance. For individuals who take the medication under medical supervision, these benefits can enhance fitness progress and support long-term health goals. However, safety and balance are key. By combining Adderall with mindful exercise practices, proper nutrition, and medical guidance, individuals can enjoy the positive effects of both physical activity and the medication while minimizing risks. TIME BUSINESS NEWS
Yahoo
a day ago
- Yahoo
Digital Health In Neurology Market to Surpass Valuation of US$ 229.5 Billion By 2033
The market is rapidly advancing, driven by sophisticated software and empowered patients. This synergy is fostering a more personalized, accessible, and data-informed approach to managing complex neurological conditions worldwide. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global digital health in neurology market was valued at US$ 38.9 billion in 2024 and is expected to reach US$ 229.5 billion by 2033, growing at a CAGR of 21.8% during the forecast period 2025–2033. Digital therapeutics (DTx) are emerging as a powerful new class of medicine. These software-based interventions deliver evidence-based therapeutic programs directly to patients. In the area of ADHD, Akili Interactive's EndeavorOTC is making significant inroads. A 2024 registry study revealed that 58.2% of its users reported having combined type ADHD. The data also highlighted significant comorbidities, with 69% of users reporting depression and 56% reporting an anxiety disorder. A remarkable 87% of users stated they had no to moderate symptom control with their existing ADHD treatments. For a quarter of users, difficulties in obtaining their medication prompted them to try EndeavorOTC in the digital health in neurology market. Download Sample Pages: Another innovation, the Revibe smartwatch for children with ADHD, demonstrated its efficacy in a study with 706 participants. Children using the device showed a more than 25-minute increase in attention span after just three weeks. The study also recorded a 19% increase in on-task behaviors. Further validation for EndeavorOTC came from a 2024 study of 220 adults, which found clear improvements in ADHD-related symptoms and overall quality of life. An earlier 2021 study of EndeavorRx for children with ADHD showed that after two months, over two-thirds of the 206 participants' parents reported improvements in their child's ADHD-related impairments. Key Findings in Digital Health in Neurology Market Market Forecast (2033) US$ 229.5 billion CAGR 21.8% Largest Region (2024) North America (39%) By End User Providers (43%) Top Drivers Increasing prevalence of neurological disorders globally. Advancements in AI and machine learning for diagnostics. Growing demand for remote patient monitoring solutions. Top Trends Integration of digital biomarkers in clinical trials. Rise of personalized digital therapeutics (DTx). Focus on consumer-centric neurological wellness applications. Top Challenges Data privacy and security concerns with sensitive health information. Ensuring equitable access to digital health technologies. Navigating complex regulatory and reimbursement landscapes. Virtual Care Platforms are Erasing Distances in Neurological Patient Management Telemedicine is dismantling traditional barriers to neurological care with remarkable speed in the digital health in neurology market. Virtual consultations and remote patient monitoring (RPM) are now standard practice, offering convenience and enhanced oversight. A 2024 survey of pediatric epilepsy providers found 67.9% of their centers now use video visits exclusively for telehealth. A vast majority, 83%, believe these platforms provide more equitable healthcare access. The removal of transportation barriers stands out as a significant driver for teleneurology adoption in 2024. Projections show that by 2025, over 71 million Americans will use some form of RPM service. The utility of telehealth is undeniable. The 2024 study also showed that 92.5% of pediatric epilepsy providers use it for reviewing test results, while 96.2% use it to discuss treatment plan changes. The financial and clinical impact is staggering. The telestroke services market is projected to reach USD 1.99 billion by 2025, with cloud-based platforms dominating 85.3% of that market. A lifetime analysis of a telestroke program revealed an average societal cost saving of $1,526 per patient. Patients also experienced an incremental gain of 0.45 quality-adjusted life years (QALYs). A separate hub-and-spoke telestroke network model demonstrated a lifetime cost saving of $1,436 per patient and a 0.02 QALY gain. A 5-year model of one such network projected an annual cost saving of $358,435 for the entire system, with each spoke hospital saving an estimated $109,080 annually. Ultimately, implementing a telestroke program was associated with a reduction of 101 nursing home residents per 10,000 patients. The digital health in neurology market is clearly benefiting from these efficiency gains. Wearable Technology Unleashes a Continuous Stream of Actionable Patient Data Wearable sensors and mobile health applications are fundamentally changing patient monitoring. They provide a continuous flow of real-world data, empowering both patients and clinicians. The digital health in neurology market is leveraging these tools for proactive disease management. In Parkinson's disease, Rune Labs' StrivePD platform saw its user network expand by 56% in 2024. A nine-month pilot study of the platform involving 138 patients yielded impressive results. Participants experienced a 42% reduction in emergency room visits and an 18% reduction in time needed with movement disorder specialists. The behavioral impact was also significant, with 90% of users increasing their exercise levels and 80% showing improved medication adherence. Rune Labs' 2024 research is powered by a rich dataset from over 1,000 Parkinson's patients using the platform. The momentum extends to other conditions as well. As of 2025, the global market for epilepsy monitoring devices is projected to be valued at an impressive USD 582.3 million. Artificial Intelligence Is Driving a New Era of Diagnostic Precision Artificial intelligence (AI) is supercharging diagnostic capabilities within digital health in neurology market. Machine learning algorithms can analyze complex medical data with unprecedented speed and accuracy. For Parkinson's disease, a condition where early diagnosis is challenging, a new AI software called Automated Imaging Differentiation for Parkinsonism (AIDP) has demonstrated the ability to increase diagnostic precision to beyond 96%. This is a monumental leap compared to the current diagnostic accuracy of 55% to 78% within the first five years. A systematic review of 127 studies on AI-driven Parkinson's diagnosis found accuracy rates consistently ranging from 78% to 96%. An experimental multimodal AI diagnostic framework achieved a 94.2% accuracy in detecting early-stage disease. A deep-learning model analyzing medical and prescription data from 820 Parkinson's patients achieved a diagnostic accuracy of 0.937 when using data from three years preceding diagnosis. When analyzing an even earlier period (3-6 years before diagnosis), the model's accuracy improved to 0.922 with the inclusion of medication data. The trend extends to other conditions, with the US FDA clearing the NeuroQuant 5.0 software, an AI-powered tool for assessing MRI scans of patients being treated for Alzheimer's disease. These advancements are a cornerstone of the digital health in neurology market. Immersive Virtual Reality Therapies Are Redefining Neurorehabilitation Possibilities Virtual Reality (VR) is creating highly engaging and effective therapeutic environments for neurological recovery. The technology is proving particularly useful for patients recovering from stroke, brain injuries, and amputations. In a groundbreaking clinical trial for phantom limb pain, a VR treatment requiring leg movements led to a 39.6% pain reduction among seven participants with lower-limb amputations. Even a distractor VR treatment without leg movements in the same study resulted in a notable 28% decrease in pain. This early success has prompted an expansion of the proof-of-concept study, which initially involved eight subjects with below-knee amputations, to a larger sample size. These immersive solutions represent a high-growth segment within the broader digital health in neurology market, offering new hope for patients undergoing difficult rehabilitation journeys. Digital Biomarkers Are Accelerating the Pace of Neurological Clinical Research Digital biomarkers are revolutionizing how researchers track disease progression and treatment efficacy. Collected via sensors and mobile devices, these objective data points provide a high-frequency view of a patient's condition. Their impact on clinical trial efficiency is profound in the digital health in neurology market. A trial simulation for a hypothetical Parkinson's digital biomarker showed it could lead to a 55.7% reduction in the number of subjects needed for a one-year trial if it detected disease progression just 1.5 times faster than standard assessments. The same simulation indicated that a digital biomarker with a 0.5-fold reduced standard deviation could allow for a trial with 70.0% fewer subjects per arm. Companies are actively building a presence in this space. As of 2024, Rune Labs, a key player focused on digital biomarkers for Parkinson's, had already participated in 15 scientific conferences to share its findings. Robust Investment and a Dynamic Competitive Landscape Signal Strong Market Confidence The financial community is taking notice of the immense potential in neurotechnology. Venture capital and strategic investments are flowing into the digital health in neurology market, fueling innovation. In 2024, European tech companies raised over €1.1 billion in seed funding, with total funding for startups reaching $51 billion. Healthcare and biotechnology was the leading investment sector, attracting over $11 billion. The median pre-seed funding round in Europe grew by 15.7% in the second half of 2024 to €870,000. Specific deals highlight this trend. In October 2024, iGent AI secured a €7.6M seed round, Nomos raised a €1.9M pre-seed round, and In Parallel secured €2.78 million. The competitive landscape is equally dynamic. Blackrock Neurotech received a massive $200 million investment from Tether in 2024, valuing the company at approximately $350 million. Its NeuroPort Array system, priced at over half a million dollars, has been sold to several dozen hospitals. Blackrock Neurotech's estimated annual revenue is $60.7 million, with an estimated revenue per employee of $306,778. Before the latest investment, the company had already raised $50 million and had seen early revenue grow from approximately $700,000 to $3.5 million. Meanwhile, Rune Labs announced a strategic $12 million investment round in 2024, bringing its total funding to $42 million. Its StrivePD platform is also being used in a care management program with Kaiser Permanente. Customize the Data Scope to Match Your Objectives: Evolving Regulations and Emerging Technologies Are Charting the Industry's Future The future of the digital health in neurology market is being shaped by evolving regulatory frameworks and next-generation technologies. Regulators are adapting to the unique nature of software-based medical devices. As of September 2023, Japan had approved only three therapeutic apps. To accelerate innovation, Japan's PMDA set a six-month target review time for priority Software as a Medical Device (SaMD) products as of January 2024. A new two-stage approval system for SaMD was also expected in 2024. Patient engagement is another critical factor. A Mayo Clinic study of its RPM program found a patient engagement rate over 78%. A latest report published in 2025 found that 62% of healthcare leaders in the digital health in neurology market believe Generative AI holds the highest potential for improving patient engagement. Indeed, a 2025 survey revealed 51% of people have already used Generative AI to help diagnose symptoms. Looking ahead, Brain-Computer Interfaces (BCIs) represent the next frontier. The global BCI market was valued at USD 2.3 billion in 2024 and is expected to soar to USD 4.5 billion by 2029. Pioneers like Blackrock Neurotech, with over 40 patients already implanted with their Digital Health In Neurology Market Key Players: AdvancedMD, Inc. Akili, Inc. AppliedVR, Inc. BigHealth Blackrock Neurotech. Cognivive, Inc. Neofect Co, Ltd Omada Health Inc. Proteus Digital Health, Inc. Teladoc Health, Inc. Other Prominent Players Key Market Segmentation: By Component Software Hardware Services By End-use Patients Providers Payers Others By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in to access your portfolio
Forbes
a day ago
- Forbes
Hospitals Are Betting On AI To Transform Neurological Diagnosis
Today, Israel-based Sheba Medical Center — the Middle East's largest medical facility and ranked among the world's top 10 hospitals — announced a joint venture with Revealense — the developer of a neurological-AI engine for analyzing and interpreting human behavior and cognitive state through video — that could bring neurological diagnostics into the home. Buoyed by AI, their idea is presented as both simple and radical all at once: A basic webcam, connected to an AI engine, could help families start assessments for autism or ADHD without ever setting foot in a clinic. Revealense supplies the behavioral-AI technology, Sheba brings the clinical expertise, and together they argue the result could be faster diagnoses, less bias and treatment plans shaped around everyday behavior. ARC (Accelerate, Redesign, Collaborate), Sheba's innovation arm, has already become one of the most active hospital-led incubators of medical technology. This new venture is part of its wider ambition to pull medicine closer to patients — to close the distance and shorten the delays that have long defined access to specialist care. 'The collaboration with Revealense exemplifies Sheba and ARC's unique innovation model — which brings together clinicians on the ground, technological excellence and robust infrastructure to establish entrepreneurial initiatives,' said Avner Halperin, CEO of Sheba Impact at ARC, in the hospital's press release. The Urgency The pressure of autism assessments is real, so the appeal of such technology is easy to understand. Autism evaluations can take months, sometimes years, and the wait can feel endless for families. In the United States, the Centers for Disease Control and Prevention reported that in 2020 about one in 36 children aged 8 was identified with autism, and by 2022 that number had risen to one in 31. While parents are often urged to seek help as early as possible, they usually face year-long delays before receiving answers. ADHD, too, has seen a surge in diagnoses, particularly during the pandemic, when families and schools began paying closer attention to attention disorders and their impact on learning. For parents navigating these waits, a tool that could offer a reliable first step from home is compelling. Earlier assessments mean earlier interventions, which are often the difference between a child thriving or falling behind. 'Beyond dramatically reducing the time needed for diagnosis, the venture also aims to enable earlier detection of syndromes, potentially allowing for initial assessments of autism and other conditions as early as 6 to 12 months of age,' explained Dr. Omer Bar Yosef, Director of the Child Development Center at Sheba Medical Center. Between Potential And Proof But bringing AI into such sensitive territory is not without challenges. Because Autism and ADHD assessments depend on a mix of structured interviews, observation across different environments and careful review of developmental history, assessing both conditions is rarely straightforward. So, without any doubts, turning that into an algorithm is quite complex and critics argue that context matters as much as raw behavior. A toddler's eye movements or gestures, for example, can mean different things depending on culture, language, or environment. There are also several regulatory hurdles to cross. In the United States, for example, the Food and Drug Administration has made clear that AI-driven diagnostic tools will face strict scrutiny, especially those that involve children. In Europe, the AI Act imposes additional requirements for high-risk medical applications. Although what Sheba and Revealense are proposing could reshape access to care, gaining approval across markets is a different game altogether and is often a long process. But both teams say they are well-prepared to go through the rigorous standards designed to protect patients and are confident that their experience in the space sets them apart from the herd. Hospitals As AI Innovators While this technology could potentially transform medical care globally, the bigger story here is about how hospitals themselves are starting to lead this kind of innovation. Sheba, for example, has built a portfolio of clinician-led startups that, according to the hospital, have already produced exits valued at nearly a billion dollars, with profits reinvested into new projects. Its ARC network now also stretches to more than 300 hospitals across 12 countries. Sheba isn't alone in pushing hospitals into the innovation arena. In another example, researchers at Seoul-based Gangnam Severance Hospital and Yonsei University recently published a review on how generative AI might help not only with autism diagnosis but also with personalized treatment plans in real time. They described AI not as an optional add-on but as something that could work alongside clinicians — a partner rather than a product. Increasingly, hospitals are diving into the world of R&D and creating new tools and systems to make medical care even better. That clinician-led model, which blends physician insight with entrepreneurial energy, is catching on very quickly and it could redefine how healthcare systems innovate going forward. As Dov Donin, cofounder and CEO of Revealense, noted, 'It's not just a new technology — it's a paradigm shift that can improve and even save lives, while elevating the entire diagnostics landscape.' But if at-home neurological diagnostics do reach mainstream use in 2026, Sheba and Revealense will be remembered for pioneering a shift in how medicine is delivered. Even if the path is slower, the venture reflects how hospitals are beginning to see AI not as an external product to purchase, but as an internal capability to shape. For families waiting months for answers, that shift holds real promise. For families waiting months for answers, that change holds promise. For healthcare itself, it suggests a new era where hospitals are not just sites of care but laboratories for the future of medicine.
